Dyne Therapeutics (NASDAQ:DYN) Coverage Initiated by Analysts at Sanford C. Bernstein

Stock analysts at Sanford C. Bernstein started coverage on shares of Dyne Therapeutics (NASDAQ:DYN - Get Free Report) in a report released on Tuesday,Briefing.com Automated Import reports. The brokerage set a "market perform" rating and a $13.00 price target on the stock. Sanford C. Bernstein's target price suggests a potential upside of 27.95% from the stock's current price.

Other research analysts have also recently issued research reports about the stock. Oppenheimer assumed coverage on shares of Dyne Therapeutics in a report on Monday, June 2nd. They issued an "outperform" rating and a $34.00 price target for the company. BMO Capital Markets assumed coverage on shares of Dyne Therapeutics in a research note on Wednesday, March 12th. They issued an "outperform" rating and a $50.00 target price on the stock. Raymond James Financial assumed coverage on Dyne Therapeutics in a research note on Wednesday, June 11th. They issued an "outperform" rating and a $37.00 price objective for the company. HC Wainwright cut their target price on shares of Dyne Therapeutics from $46.00 to $38.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Finally, Chardan Capital reaffirmed a "buy" rating and set a $50.00 price objective on shares of Dyne Therapeutics in a research report on Tuesday, June 17th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Dyne Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $41.87.

Dyne Therapeutics Stock Performance

DYN stock opened at $10.16 on Tuesday. Dyne Therapeutics has a one year low of $6.36 and a one year high of $47.45. The firm has a market cap of $1.15 billion, a price-to-earnings ratio of -2.83 and a beta of 1.17. The firm has a 50-day simple moving average of $11.66 and a two-hundred day simple moving average of $14.26.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($1.05) EPS for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.17). As a group, equities analysts predict that Dyne Therapeutics will post -3.44 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. RA Capital Management L.P. grew its holdings in Dyne Therapeutics by 52.2% during the 1st quarter. RA Capital Management L.P. now owns 9,714,392 shares of the company's stock valued at $101,613,000 after buying an additional 3,333,248 shares during the last quarter. Atlas Venture Life Science Advisors LLC lifted its holdings in shares of Dyne Therapeutics by 13.9% during the 1st quarter. Atlas Venture Life Science Advisors LLC now owns 9,130,465 shares of the company's stock worth $95,505,000 after acquiring an additional 1,111,111 shares during the period. Vanguard Group Inc. raised its stake in Dyne Therapeutics by 10.5% during the first quarter. Vanguard Group Inc. now owns 7,406,344 shares of the company's stock worth $77,470,000 after purchasing an additional 702,418 shares during the period. Janus Henderson Group PLC raised its position in shares of Dyne Therapeutics by 8.3% in the 4th quarter. Janus Henderson Group PLC now owns 7,379,309 shares of the company's stock worth $173,808,000 after buying an additional 566,146 shares during the period. Finally, Braidwell LP lifted its stake in shares of Dyne Therapeutics by 431.6% in the 1st quarter. Braidwell LP now owns 3,621,344 shares of the company's stock valued at $37,879,000 after purchasing an additional 2,940,162 shares in the last quarter. Hedge funds and other institutional investors own 96.68% of the company's stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.